Diabetes Technology Meeting 2022 put automation, data integration, and sensing at center stage
The 2022 Diabetes Technology Meeting gathered a broad clinical agenda under one roof, but the common thread was unmistakable: diabetes care is moving toward tighter sensing, faster feedback, and more automated decision-making. Diabetes Technology Society held the annual meeting from November 3 to November 5, 2022, and the program reflected how far the field has expanded beyond glucose monitoring alone. The sessions ranged from glucose, insulin, and ketone measurement to fully automated insulin delivery systems, virtual diabetes care, and the integration of continuous glucose monitor data into the electronic health record.
A meeting built around devices can still reveal a great deal about bedside medicine. Each technology discussed in this program addresses a specific failure point in diabetes management: missed hypoglycemia, delayed dose adjustment, incomplete data review, poor carbohydrate estimation, or the practical burden of self-management. The breadth of topics also shows how diabetes technology has become an ecosystem rather than a single product category. Sensors, software, delivery platforms, and clinician-facing records now have to work together if they are going to change daily care in a meaningful way.
Continuous glucose monitoring and automated insulin delivery dominated the clinical agenda
Continuous glucose monitoring remained one of the central pillars of the program. Sessions addressed continuous glucose monitoring itself, metrics for managing diabetes and predicting outcomes, and the use of device data to support more precise treatment decisions. In parallel, the meeting gave substantial attention to fully automated insulin delivery systems, a category that depends on the reliability of glucose sensing and the speed of insulin response. The therapeutic logic is straightforward even if the engineering is not: better sensing allows insulin dosing to adapt more closely to changing physiology, with the goal of reducing both hyperglycemia and hypoglycemia.
Insulin delivery was also treated as a separate problem rather than an afterthought. That is clinically important because delivery failures, user error, and device burden all shape real-world outcomes. Novel insulins appeared on the agenda as well, reflecting the continuing need for formulations that can better match rapid glucose excursions and support automated systems. When insulin kinetics and sensor performance improve together, the entire treatment loop becomes more responsive.
Hypoglycemia received dedicated attention, and for good reason. No diabetes technology can be judged only by its ability to lower average glucose; preventing dangerous lows remains a central safety test. A system that improves glycemic control while leaving patients vulnerable to unrecognized hypoglycemia would not represent progress at the bedside. The meeting’s structure suggests that safer automation remains the field’s immediate design challenge.
Digital infrastructure was treated as part of treatment, not just administration
Several sessions focused on the digital plumbing required to make modern diabetes care work in routine practice. Virtual diabetes care was on the agenda, as was the integration of continuous glucose monitor data into the electronic health record. Those topics may sound administrative, but they determine whether clinicians can actually act on device information in a timely way. If glucose data are trapped in a separate platform, they are less likely to shape medication adjustments, counseling, or follow-up decisions.
Digital health to nudge behavior and estimating carbohydrates were also included, linking technology with the everyday choices that determine glucose patterns. Carbohydrate estimation remains one of the most error-prone parts of diabetes self-management, and digital tools are being asked to reduce that uncertainty without making treatment more cumbersome. The meeting also addressed regulation of diabetes technology, a reminder that innovation in this field depends on oversight, interoperability, and safe deployment as much as on engineering advances.
One sentence captures the clinical reality: a sensor that cannot be acted on quickly is only half a tool.
Beyond glucose control, the meeting widened to complications and broader patient burden
The program did not stop with glucose metrics. It included diabetic foot ulcers, spinal cord stimulation for painful diabetic neuropathy, and on-body sensors, showing that diabetes technology is increasingly relevant across complications and symptom management. Diabetic foot ulcers remain a major clinical problem because they sit at the intersection of neuropathy, vascular disease, infection risk, and wound healing. Any technology aimed at earlier detection or better management has potential consequences far beyond glucose numbers.
Spinal cord stimulation for painful diabetic neuropathy also points to a different kind of burden: chronic neuropathic pain can be disabling even when glycemic management is acceptable. By including this topic, the meeting acknowledged that diabetes technology is not only about metabolic control. It also reaches into quality of life, symptom relief, and the long-term complications that define the disease for many patients.
On-body sensors widened the discussion still further. Wearable platforms are moving toward smaller footprints and more continuous data capture, which may improve adherence and reduce friction in daily use. Yet each new device adds its own issues of wearability, maintenance, and interpretation. The practical success of a sensor depends not just on accuracy, but on whether patients and clinicians can keep using it consistently.
Sustainability and device recycling entered the diabetes conversation
A live demonstration of a device designed to allow recycling of used insulin pens added an unusual but relevant dimension to the meeting. Environmental impact is now part of diabetes technology discussions, and for good reason. Devices used every day by millions of people generate substantial material waste, and that burden has been largely invisible in clinical conversations. Recycling used insulin pens does not change glycemic targets, but it does address the real-world footprint of chronic disease management.
This is where the meeting’s scope became especially revealing. Diabetes technology is no longer measured only by glucose excursions or A1c-adjacent thinking. It is also being judged by how well it fits into the health system, how much burden it places on patients, how safely it can be regulated, and how sustainably it can be used over time. The field’s next advances will likely be shaped by whether these pieces can finally be linked into a coherent workflow.
The 2022 program did not present a single breakthrough result or a lone defining device. Instead, it mapped the priorities of a specialty that is trying to make diabetes management more continuous, more automated, and more usable in daily life. The unresolved questions are practical ones: which tools are accurate enough, which systems are interoperable enough, and which innovations can truly reduce the burden of care without shifting that burden elsewhere.